SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: JS Ogrady who wrote (125)7/10/1998 11:58:00 AM
From: Diane  Read Replies (1) | Respond to of 416
 
Good news from Briefing.com:

MedImmune Inc. (MEDI) 62 3/4 -1 1/8: Adams Harkness initiates coverage of developer and marketer of therapeutics and vaccines with "buy" and a year-end price target of $83; company granted FDA approval for Synagis, a monoclonal antibody to replace RespiGam, expects Synagis sales of $162 mln in FY98, $251 mln in FY99, $326 mln in FY00 and $429 mln in FY01; expects company to earn $0.08 in FY98 and $1.80 in FY99.....



To: JS Ogrady who wrote (125)8/22/1998 11:18:00 AM
From: Bioscoop  Respond to of 416
 
How much more use will the new vaccine, Synagis get compared to Respigam due to its easier smaller dose, intramuscular formulation vs i.v in the scalp. The efficacy doesn't appear to be any better as a randomized study hasnt' been done.

In what patient population has Respigam been used historically and in which population do you see Synagis being expanded into this winter?

Thank you for your time.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News